House GOP Proposes Health Care Package as ACA Subsidies Near Expiration

The U.S. Senate failed to advance any health care legislation this week, shifting the focus to the House of Representatives to act before year-end deadlines. House Speaker Mike Johnson introduced a comprehensive Republican health care package aimed at addressing key cost drivers, including expanding association health plans and increasing data transparency from pharmacy benefit managers (PBMs) to control drug prices. This proposal notably does not extend the enhanced Affordable Care Act (ACA) tax subsidies, which are set to expire on December 31, 2023, potentially resulting in significant premium increases for millions of Americans. The Republican package emphasizes access to employer-sponsored plans and regulatory oversight of PBMs, which critics argue affect drug pricing and independent pharmacies. It proposes delayed cost-sharing reductions for low-income ACA enrollees, effective in 2027, but excludes continuation of current enhanced subsidies. Meanwhile, internal GOP divisions are emerging, with some moderate Republicans aligning with Democrats to pursue temporary extensions of ACA tax credits through bipartisan discharge petitions that could force House votes despite leadership opposition. These discharge petitions represent a strategic legislative tool to bypass party control and potentially enact short-term relief for Americans facing rising health insurance costs. One petition seeks a two-year extension with anti-fraud and PBM oversight measures, while another aims for a one-year subsidy extension with income eligibility caps. Democratic leaders have expressed cautious consideration but have yet to endorse either. Speaker Johnson’s package contrasts with Senate GOP proposals that included health savings account contributions; the House plan lacks such features. The debate reflects broader ideological divides within the Republican caucus regarding ACA policies and the best methods to reduce health care expenses. As congressional sessions near adjournment, consensus remains elusive. Failure to extend ACA subsidies could lead to increased premiums and reduced coverage affordability, impacting health insurance market dynamics and potentially increasing uninsured rates. Ongoing negotiations underscore tensions between fiscal conservatism and the urgency of mitigating health care cost growth for vulnerable populations. Health care insurance stakeholders, including payers, providers, and policy analysts, must monitor these legislative developments closely due to their implications for market regulation, insurance affordability, and PBM operations. The evolving landscape highlights the interplay between regulatory proposals and their practical effects on coverage access and pharmaceutical cost management within the U.S. health insurance market.